PTGX - NASDAQ
Protagonist Therapeutics, Inc.
$95.41
+1.5%Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
At a Glance
Live Snapshotptgx
Property, Plant, and Equipment (Net)
Last Annual Value
11.69M
3-Year CAGR
36%
5-Year CAGR
13%
10-Year CAGR
34%
Protagonist Therapeutics, Inc. Competitors Analysis of Property, Plant, and Equipment (Net)
| Company | Property, Plant, and Equipment (Net) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Protagonist Therapeutics, Inc. NASDAQ:PTGX | 11.69M | 75.9% | 11.7% | 35.5% | |
 PTC Therapeutics, Inc. NASDAQ:PTCT | 135.42M | -8.9% | 0.8% | 33.7% | |
 TG Therapeutics, Inc. NASDAQ:TGTX | 6.28M | -8.0% | -10.7% | 10.2% | |
 Akero Therapeutics, Inc. NASDAQ:AKRO | 755.00K | -9.7% | -13.4% | N/A | |
 Alkermes plc NASDAQ:ALKS | 298.93M | -2.1% | -8.1% | 1.2% | |
 Immunovant, Inc. NASDAQ:IMVT | 515.00K | -30.1% | -31.8% | N/A | |
 Arcellx, Inc. NASDAQ:ACLX | 0.00 | N/A | N/A | N/A | |
 NewAmsterdam Pharma Company N.V. NASDAQ:NAMS | 568.00K | 77.8% | 21.3% | N/A | |
 Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX | 54.79M | -1.6% | 63.3% | 73.3% | |
 Viking Therapeutics, Inc. NASDAQ:VKTX | 85.00K | -57.7% | 27.7% | N/A | |
 Kymera Therapeutics, Inc. NASDAQ:KYMR | 85.53M | -5.4% | 32.0% | N/A |
Protagonist Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your PTGX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.